79.91
1.76 (2.25%)
| Penutupan Terdahulu | 78.15 |
| Buka | 78.07 |
| Jumlah Dagangan | 2,665,465 |
| Purata Dagangan (3B) | 2,533,067 |
| Modal Pasaran | 15,399,362,560 |
| Harga / Jualan (P/S) | 41.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Feb 2026 |
| Margin Operasi (TTM) | -89.00% |
| EPS Cair (TTM) | -3.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -44.80% |
| Nisbah Semasa (MRQ) | 4.57 |
| Aliran Tunai Operasi (OCF TTM) | -500.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -261.20 M |
| Pulangan Atas Aset (ROA TTM) | -48.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BridgeBio Pharma, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -1.30 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.97% |
| % Dimiliki oleh Institusi | 98.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aisling Capital Management Lp | 30 Sep 2025 | 6,089,611 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (Cantor Fitzgerald, 37.66%) | Beli |
| Median | 92.00 (15.13%) | |
| Rendah | 71.00 (Raymond James, -11.15%) | Beli |
| Purata | 90.92 (13.78%) | |
| Jumlah | 12 Beli | |
| Harga Purata @ Panggilan | 67.79 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 20 Jan 2026 | 88.00 (10.12%) | Beli | 77.19 |
| 11 Nov 2025 | 84.00 (5.12%) | Beli | 66.58 | |
| Truist Securities | 08 Jan 2026 | 86.00 (7.62%) | Beli | 73.82 |
| 30 Oct 2025 | 80.00 (0.11%) | Beli | 63.37 | |
| Morgan Stanley | 06 Jan 2026 | 96.00 (20.14%) | Beli | 73.99 |
| Leerink Partners | 15 Dec 2025 | 86.00 (7.62%) | Beli | 74.51 |
| Bernstein | 11 Dec 2025 | 94.00 (17.63%) | Beli | 74.07 |
| JP Morgan | 07 Nov 2025 | 77.00 (-3.64%) | Beli | 61.80 |
| HC Wainwright & Co. | 03 Nov 2025 | 90.00 (12.63%) | Beli | 61.98 |
| 29 Oct 2025 | 90.00 (12.63%) | Beli | 66.62 | |
| Goldman Sachs | 31 Oct 2025 | 100.00 (25.14%) | Beli | 62.64 |
| Cantor Fitzgerald | 30 Oct 2025 | 110.00 (37.65%) | Beli | 63.37 |
| Piper Sandler | 30 Oct 2025 | 98.00 (22.64%) | Beli | 63.37 |
| Raymond James | 30 Oct 2025 | 71.00 (-11.15%) | Beli | 63.37 |
| TD Cowen | 30 Oct 2025 | 95.00 (18.88%) | Beli | 63.37 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |